Cvs Health president Prem S Shah buys $2.0 million of shares
Open market purchase reported on Form 4, filed Nov 6, 2026.
Snapshot
Prem S Shah, EVP and Group President of Cvs Health (CVS), bought 23,855 shares in open market purchases on Nov 6, 2026, about $2.0 million at an average price of $83.89 a share, according to a Form 4 filed with the SEC on Nov 6, 2026.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($CVS) | ▲ +3.10% | 83.85 |
as of 16:00 ET · Realtime derived data
What We Know
The filing lists 1 open market purchase line: • Nov 6, 2026: 23,855 shares at $83.89.
After the last purchase, the filing reports 88,516.16 shares held directly in that account.
Octans View
The purchases raised the holding reported in that account by about 37%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought.
Bear Case · Room for Disagreement
Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.
Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — Form 4 filed by Prem S Shah for Cvs Health, Nov 6, 2026
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
$2.0M
More on $CVS
4 reports
CVS Health quarterly revenue rises 5.4% to $108.40 billion
CVS Health's revenue growth is slowing. Results for the quarter ended September 30, 2026, from the earnings release filed with the SEC on Nov 4, 2026.
Annovis Bio director Michael B Hoffman buys $5.0 million of shares
Open market purchase reported on Form 4, filed Nov 6, 2026.
Kinder Morgan chair Richard D Kinder buys $15.0 million of shares
Open market purchase reported on Form 4, filed Nov 6, 2026.
Madrigal Pharmaceuticals director Baker Bros. Advisors Lp buys $35.0 million of shares
Open market purchase reported on Form 4, filed Nov 6, 2026.